Back to today’s briefing

Story perspectives

Moderna and Merck's Cancer Therapy Cuts Recurrence by 49%

1/21/2026

39 7

Summary

Story summary

Moderna and Merck announced five-year results from a Phase 2b study of intismeran autogene with Keytruda for advanced melanoma, showing a 49% reduction in recurrence or death versus Keytruda alone.
The data build on analyses at two and three years.
Firms are advancing intismeran autogene trials for lung cancer and renal cell carcinoma.
Analysts expect sustained results and a potential market by 2027.
Moderna's stock rose 2.8% after the announcement.

1 of 1

Story summary

Moderna and Merck announced five-year results from a Phase 2b study of intismeran autogene with Keytruda for advanced melanoma, showing a 49% reduction in recurrence or death versus Keytruda alone.
The data build on analyses at two and three years.
Firms are advancing intismeran autogene trials for lung cancer and renal cell carcinoma.
Analysts expect sustained results and a potential market by 2027.
Moderna's stock rose 2.8% after the announcement.